***To the Editor:*** The coronavirus disease 2019 (COVID-19) pandemic has resulted in a debate on potential risks vs benefits of certain pharmaceuticals---angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). A recent letter to the editor, published in the *Journal of Travel Medicine*,[@bib1] outlined a hypothesis stating that the use of ACEIs and ARBs may increase the risk of severe disease in patients with COVID-19. Data suggested that the intravenous infusion of ACEIs and ARBs in experimental animals increased the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. It is acknowledged that ACE2 receptors are widely dispersed, including lung alveolar epithelial cells, gastrointestinal tract enterocytes, the vascular system, the nasopharynx, kidney, and brain.[@bib2]

Based on those preclinical data, recognizing that ACE2 receptors are binding sites for coronavirus entry into the body, an increased number of ACE2 receptors was hypothesized to increase the risk of severe pulmonary disease by increasing the number of binding sites available to the virus. Although that conclusion is persuasive at first glance, the data and recommendations presented in the accompanying article by Sanchis-Gomar et al[@bib3] and the recent article by Vaduganathan et al[@bib4] are more compelling. Further analysis of ACE2 mechanisms supports the hypothesis that ACEIs and ARBs are more likely to benefit than harm patients with COVID-19. Coronavirus disease 2019 binds the viral S protein to ACE2, reducing receptor expression, enabling viral and cell membrane fusion and viral replication, with the potential for inflammatory tissue damage, and the severe inflammatory response---a cytokine storm.

At infection onset, an initial inflammatory response is triggered with the production of angiotensin II, via renin-angiotensin-aldosterone system activation (nicely reviewed in the article). This inflammatory response is normally moderated by the activation of ACE2 receptors. Angiotensin-converting enzyme 2 is a key player in minimizing and reversing the inflammatory response by converting angiotensin II to angiotensin 1-7 (Ang 1-7), which, after binding to the Mas receptor, results in a wide array of anti-inflammatory actions.[@bib5] The inflammatory state is a critical organismal response to an invader, but ultimately healing requires inflammation resolution, a process blocked by COVID-19's binding to the cellular membrane ACE2 and downregulating ACE2 expression in host cells, leading to unrelenting inflammation.

The proposal that increased numbers of ACE2 receptors, owing to ACEIs and ARBs, would signal an increase in viral binding and severe disease is unsupported by clinical data. The alternative view that the presence of more functional ACE2 receptors could facilitate inflammation resolution by increasing the production of anti-inflammatory Ang 1-7 is reasonable. More Ang 1-7 would promote and support healthy vascular, pulmonary, myocardial, and renal function and suppress inflammatory cytokine production. If ACEIs and ARBs increase functional ACE2 receptors, the activation of anti-inflammatory pathways may save lives.

Pending more research on this topic and lacking evidence of harm to patients with COVID-19 while taking ACEIs and ARBs, discontinuation of these medications is unjustified and could result in more negative outcomes.
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